Ovarian cancers arising from endometriosis: A microenvironmental biomarker study including ER, HNF1ß, p53, PTEN, BAF250a, and COX-2

Journal of the Chinese Medical Association

Volumn 76, Issue 11, 2013, Pages 629-634

  Lai, Chiung Ru ^a,b   Hsu, Chih Yi ^a,b   Chen, Yi Jen ^a,b   Yen, Ming Shyen ^a,b   Chao, Kuan Chong ^a,b   Li, Anna Fen Yau ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Biomarkers; Endometriosis; Ovarian neoplasms

Indexed keywords

BAF250A PROTEIN; BIOLOGICAL MARKER; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1BETA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADENOSARCOMA; ADENOSQUAMOUS CARCINOMA; ARTICLE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TAIWAN;

BIOMARKERS; ENDOMETRIOSIS; OVARIAN NEOPLASMS;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; CYCLOOXYGENASE 2; ENDOMETRIOSIS; FEMALE; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PTEN PHOSPHOHYDROLASE; RECEPTORS, ESTROGEN; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84886091922     PISSN: 17264901     EISSN: 17287731     Source Type: Journal    
DOI: 10.1016/j.jcma.2013.07.008     Document Type: Article

References (30)

1. Eskenazi B., Warner M.L. Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997, 24:235-258.
2. Borgfeldt C., Andolf E. Cancer risk after hospital discharge diagnosis of benign ovarian cysts and endometriosis. Acta Obstet Gynecol Scand 2004, 83:395-400.
3. Melin A., Sparen P., Persson I., Bergqvist A. Endometriosis and the risk of cancer with special emphasis on ovarian cancer. Hum Reprod 2006, 21:1237-1242.
4. Kobayashi H., Sumimoto K., Moniwa N., Imai M., Takakura K., Kuromaki T., et al. Risk of developing ovarian cancer among women with ovarian endometrioma: a cohort study in Shizuoka, Japan. Int J Gynecol Cancer 2007, 17:37-43.
5. Aris A. Endometriosis-associated ovarian cancer: a ten-year cohort study of women living in the Estrie Region of Quebec, Canada. J Ovarian Res 2010, 3:2.
6. Van Gorp T., Amant F., Neven P., Vergote I., Moerman P. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 2004, 18:349-371.
7. Sampson J.A. Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch Surg 1925, 10:1-72.
8. Scott R.B. Malignant changes in endometriosis. Obstet Gynecol 1953, 2:283-289.
9. Nishida M., Watanabe K., Sato N., Ichikawa Y. Malignant transformation of ovarian endometriosis. Gynecol Obstet Invest 2000, 50(Suppl 1):18-25.
10. Kobayashi H. Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis. Int J Clin Oncol 2009, 14:378-382.
11. Mandai M., Yamaguchi K., Matsumura N., Baba T., Konishi I. Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. Int J Clin Oncol 2009, 14:383-391.
12. Xu B., Hamada S., Kusuki I., Itoh R., Kitawaki J. Possible involvement of loss of heterozygosity in malignant transformation of ovarian endometriosis. Gynecol Oncol 2011, 120:239-246.
13. Gounaris I., Charnock-Jones D.S., Brenton J.D. Ovarian clear cell carcinoma-bad endometriosis or bad endometrium?. J Pathol 2011, 225:157-160.
14. Kokcu A. Relationship between endometriosis and cancer from current perspective. Arch Gynecol Obstet 2011, 284:1473-1479.
15. Munksgaard P.S., Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol 2012, 124:164-169.
16. Yamamoto S., Tsuda H., Takano M., Tamai S., Matsubara O. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol 2012, 25:615-624.
17. DeLair D., Oliva E., Kobel M., Macias A., Gilks C.B., Soslow R.A. Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol 2011, 35:36-44.
18. Remmele W., Schicketanz K.H. Immunohistochemical determination of estrogen and progesterone receptor content in human breast cancer. Computer-assisted image analysis (QIC score) vs. subjective grading (IRS). Pathol Res Pract 1993, 189:862-866.
19. Alkushi A., Lim P., Coldman A., Huntsman D., Miller D., Gilks C.B. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004, 23:129-137.
20. Oxholm D., Knudsen U.B., Kryger-Baggesen N., Ravn P. Postmenopausal endometriosis. Acta Obstet Gynecol Scand 2007, 86:1158-1164.
21. Schwartz D.R., Kardia S.L., Shedden K.A., Kuick R., Michailidis G., Taylor J.M., et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 2002, 62:4722-4729.
22. Tsuchiya A., Sakamoto M., Yasuda J., Chuma M., Ohta T., Ohki M., et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 2003, 163:2503-2512.
23. Kato N., Sasou S., Motoyama T. Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 2006, 19:83-89.
24. Goff B.A., Sainz de la Cuesta R., Muntz H.G., Fleischhacker D., Ek M., Rice L.W., et al. Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 1996, 60:412-417.
25. Carli C., Metz C.N., Al-Abed Y., Naccache P.H., Akoum A. Up-regulation of cyclooxygenase-2 expression and prostaglandin E2 production in human endometriotic cells by macrophage migration inhibitory factor: involvement of novel kinase signaling pathways. Endocrinology 2009, 150:3128-3137.
26. Chou Y.C., Chen Y.J., Lai C.R., Wang P.H., Hsin C., Yuan C.C. Cyclooxygenase-2 expression is higher in ovarian cancer tissue adjacent to endometriosis than in ovarian cancer without comorbid endometriosis. Eur J Obstet Gynecol Reprod Biol 2006, 124:101-105.
27. Sato N., Tsunoda H., Nishida M., Morishita Y., Takimoto Y., Kubo T., et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000, 60:7052-7056.
28. Jones S., Wang T.L., Shih Ie M., Mao T.L., Nakayama K., Roden R., et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010, 330:228-231.
29. Wiegand K.C., Shah S.P., Al-Agha O.M., Zhao Y., Tse K., Zeng T., et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010, 363:1532-1543.
30. Wiegand K.C., Lee A.F., Al-Agha O.M., Chow C., Kalloger S.E., Scott D.W., et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011, 224:328-333.